Monoclonal antibodies for treatment of cancer
View Patent ↗The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
1. An isolated antibody having the ability of binding to an epitope located within the extracellular domain of the protein comprising the amino acid sequence of SEQ ID NO: 2 and mediating inhibition of proliferation of cells, wherein said cells express a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO: 2 with their cell surface.
2. The isolated antibody of claim 1 wherein said inhibition of proliferation of said cells is induced by binding of said antibody to the protein.
3. The isolated antibody of claim 1 wherein said cells are cancer cells.
4. The isolated antibody of claim 3 , wherein said cancer cells are selected from the group consisting of tumorigenic breast, lung, gastric, ovarian, liver, colon, pancreatic, esophageal, head-neck, renal, prostate and hepatocellular cancer cells.
5. The isolated antibody of claim 1 which is a monoclonal, chimeric, human or humanized antibody, or an antigen-binding fragment of an antibody.
6. The isolated antibody of claim 1 , selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody.
7. The isolated antibody of claim 6 selected from the group consisting of an IgG2a and an IgG2b antibody.
8. The isolated antibody of claim 1 wherein the amino acid sequence of said protein consists of the amino acid sequence according to SEQ ID NO: 2.
9. The isolated antibody of claim 1 wherein the antibody binds specifically to a protein comprising the amino acid sequence of SEQ ID NO: 2.
10. The isolated antibody of claim 1 which binds to a conformational epitope of a protein comprising the amino acid sequence of SEQ ID NO: 2 present on the surface of living cells.
11. The isolated antibody of claim 1 wherein said protein comprising the amino acid sequence of SEQ ID NO: 2 is expressed on the surface of said cells.
12. The isolated antibody of claim 1 which is obtainable by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2-10 and 35-79, or an immunogenic fragment or derivative thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment or derivative thereof.
13. An isolated antibody produced by a clone deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A10), or DSM ACC2898 (4E9 1D12 2D4).
14. A hybridoma capable of producing the antibody of claim 1 .
15. A hybridoma deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A10), or DSM ACC2898 (4E9 1D12 2D4).
16. A conjugate comprising an antibody of claim 1 , coupled to a therapeutic agent.
17. The conjugate of claim 16 , wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.
18. A conjugate comprising an antibody of claim 13 , coupled to a therapeutic agent.
19. The conjugate of claim 18 , wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.
20. A pharmaceutical composition comprising an antibody of claim 1 , and a pharmaceutically acceptable carrier.
21. A pharmaceutical composition comprising an antibody of claim 13 , and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising a conjugate of claim 16 , and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising a conjugate of claim 18 , and a pharmaceutically acceptable carrier.